MiR-126 prevents hypoxic HUVEC cellular injury through targeting TRAF6 expression

Area of Science:

• Biochemistry
• Molecular Biology
• Cardiovascular Research

Background:

• Coronary Artery Disease (CAD) poses a significant global health challenge.
• Identifying reliable biomarkers for CAD severity and developing protective strategies are crucial.

Purpose of the Study:

• To assess the clinical utility of miR-126 in determining CAD severity.
• To elucidate the protective role of miR-126 in hypoxic injury to human umbilical vein endothelial cells (HUVEC).

Main Methods:

• Quantitative real-time PCR (qRT-PCR) to measure miRNA and mRNA expression.
• Receiver Operating Characteristic (ROC) analysis to determine CAD severity.
• In vitro experiments on hypoxic HUVEC to evaluate miR-126's protective effects.

Main Results:

• Plasma miR-126 levels were significantly lower in CAD patients, correlating with disease severity.
• miR-126 expression was reduced in hypoxic HUVEC.
• Overexpression of miR-126 attenuated hypoxic injury markers (ROS, LDH, caspase-3) and TRAF6 levels, enhancing HUVEC viability.

Conclusions:

• Downregulated miR-126 serves as a biomarker for early CAD detection and grading.
• miR-126 demonstrates a protective mechanism against hypoxic stress in HUVEC by targeting TRAF6, offering a potential therapeutic target for CAD.